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Background: Access to a primary care physician (PCP) improves
health outcomes among patients with hypertension. The study objec-
tive was to compare PCP use among patients with incident hyperten-
sion with and without comorbidities.
Methods: Hypertensive patients newly diagnosed between April 1,
1998 and March 31, 2009 were identiﬁed using Alberta administrative
databases. Three comorbidity subgroups were deﬁned: (1) none, (2)
vascular risk related, and (3) unrelated. The number of PCP visits was
calculated using zero-inﬂation Poisson regression, with time trends
compared using the c2 test. A Cox model was used to assess the
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ORESUME
Introduction : L’accès à un medecin de première ligne (MPL)
ameliore les resultats cliniques des patients souffrant d’hypertension.
L’objectif de l’etude etait de comparer le recours à un MPL parmi
les patients souffrant d’une hypertension associee ou non à des
comorbidites.
Methodes : Les patients hypertendus ayant nouvellement ete diag-
nostiques entre le 1er avril 1998 et le 31 mars 2009 ont ete trouves en
utilisant les bases de donnees administratives de l’Alberta. Trois (3)
sous-groupes de comorbidites ont ete deﬁnis : 1) aucune; 2) risque
vasculaire associe; 3) non associee. Le nombre de visites chez le MPL
a ete calcule en utilisant la regression de Poisson à inﬂation zero, avecHypertension is 1 of the most common chronic conditions
worldwide,1 affecting 23% of the Canadian adult population.2
It is an important modiﬁable risk factor for cardiovascular
disease and the most common attributable cause for mortality
in the world.3,4 More patients visit primary care physicians
(PCPs) and receive prescriptions for the treatment of hyper-
tension than for any other medical disorder,5,6 with more than4 million prescriptions for antihypertensive medications
written every month in Canada.7 The cost in high-income
countries’ health care systems to manage patients with hy-
pertension and related complications is estimated to consume
10% of all health care spending.8,9
A better understanding of the use health care resources for
hypertension will enable targeted strategies to be developed to
facilitate more cost-effective care. Even small changes in health
care costs to manage hypertension will have a large overall
impact given the high prevalence of hypertension in Canada.
With an aging Canadian population, it is expected that there
will be an increase in the burden of hypertension-related
chronic illnesses, multiple comorbidities, and disability as
well as the demand for health care services.10 Hypertension
Canada consists of policy makers and health care professionalspen access under CC BY-NC-ND license.
Results: Of 456,263 newly diagnosed hypertensive patients (mean
age, 57.6 years; 50.6% men; 62.5% no comorbidity), 88% had seen a
PCP in the year before diagnosis, and 94% had seen a PCP in the year
after being diagnosed. Compared with before diagnosis, the mean
number of PCP visits increased after diagnosis (none, 3.95 vs 6.15;
vascular risk related, 6.45 vs 7.99; and unrelated, 6.76 vs 8.24). Over
the study period, the frequency of PCP visits before diagnosis was
constant, and there was a statistically signiﬁcant decline in the
adjusted mean number of visits after diagnosis. Those with higher PCP
use were less likely to die but more likely to be hospitalized regardless
of comorbidity.
Conclusions: The frequency of PCP visits was high before and after
diagnosis. Increased PCP use was associated with a lower risk of
death; however, it does increase the costs of caring for patients with
hypertension. Therefore, future studies are necessary to determine the
optimal level required to achieve cost-effective use of PCP resources.
les tendances temporelles comparees par le test du c2. Un modèle de
Cox a ete utilise pour evaluer le lien entre le recours à un MPL et les
resultats cliniques.
Resultats : Parmi les 456 263 patients hypertendus nouvellement
diagnostiques (âge moyen, 57,6 ans; 50,6 % d’hommes; 62,5 % sans
comorbidites), 88 % avaient rencontre un MPL au cours de l’annee qui
avait precede le diagnostic, et 94 % avaient rencontre un MPL au
cours de l’annee après avoir reçu le diagnostic. Comparativement à
ceux qui avaient rencontre le MPL avant le diagnostic, le nombre
moyen de visites chez le MPL augmentaient chez ceux qui avaient
rencontre le MPL après le diagnostic (aucune, 3,95 vs 6,15; risque
vasculaire associe, 6,45 vs 7,99 et non associee, 6,76 vs 8,24). Au
cours de la periode d’etude, la frequence des visites chez le MPL avant
le diagnostic a ete constante, et un declin statistiquement signiﬁcatif
du nombre moyen ajuste de visites après le diagnostic a ete observe.
Ceux ayant le plus recours au MPL etaient moins susceptibles de
mourir, mais plus susceptibles d’être hospitalises independamment de
la comorbidite.
Conclusions : La frequence des visites chez le MPL a ete elevee avant
et après le diagnostic. L’augmentation du recours au MPL a ete
associee à un risque plus faible de mortalite. Cependant, il augmente
le coût des soins des patients souffrant d’hypertension. Par con-
sequent, d’autres etudes sont necessaires pour determiner le niveau
optimal requis pour atteindre un bon rapport coût-efﬁcacite du recours
aux effectifs du MPL.
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Volume 30 2014who have made extensive efforts to improve hypertension
detection and management through the development of
ongoing national knowledge translation strategies.11,12
Currently in Canada, there are no mechanisms in place to
monitor hypertension management, hypertension-related
outcomes, and health care resource implications. Inefﬁcient
care will lead to a signiﬁcant burden on publically funded
health care systems through either inefﬁcient management or
excess hypertension-attributable end-organ complications,
with attendant implications on health and health care costs.
Thus, at a time of unprecedented pressure on our health care
system, health care leaders are driven to reduce waste and
inefﬁciency. Identifying inefﬁciencies and factors associated
with clinical care gaps in hypertension management is
imperative for designing policy and intervention programs to
close care gaps.
To the best of our knowledge, no studies have documented
the pattern of PCP visits after a new diagnosis of hypertension
in the universal health care system in Canada and whether the
frequency of these visits varies with the presence of other
comorbid conditions and socioeconomic factors. Given the
prevalence and importance of hypertension in the outpatient
setting, particularly PCP ofﬁces, this study focused on eval-
uating the PCP use patterns among patients with incident
hypertension with and without other comorbidities.Methods
Data sources
Administrative health databases from Alberta were linked
using an anonymized unique personal identiﬁer. The study
databases included provincial health insurance registries,
hospital discharge abstracts, and physician billing claims. TheAlberta insurance registry contains demographic information
including date of birth, sex, and mailing address for all resi-
dents of the province eligible to receive health services.
Discharge abstracts contain clinical information for all hos-
pitalized patients, with up to 25 diagnosis codes recorded for
each hospitalization using the International Classiﬁcation of
Diseases (ICD), Ninth Revision (ICD-9) and the ICD-9
Clinical Modiﬁcation (ICD-9-CM) before April 2002 or the
ICD-10 Canadian Modiﬁcation (ICD-10-CA) after April
2002.13-15 Physician billing claims contain fee-for-service
billing information that includes a unique physician identi-
ﬁer and ICD-9 codes for services provided. At least 1 and up
to 3 ICD-9 codes are recorded, corresponding to the primary
reasons for each physician visit. Physicians submit claims for
payment or reporting services to provincial government in-
surance programs. The physician claims capture outpatient
physician services and the majority of inpatient physician
services, and each claim records the billing physician’s
specialist type.Study population
We deﬁned a cohort of patients newly diagnosed with
hypertension between April 1, 1998 and March 31, 2009
(ﬁscal years 1998-2008). Hypertension cases were identiﬁed
using a previously validated case deﬁnition for Canadian
hospital discharge and physician claims administrative data-
bases, which was 75% sensitive and 94% speciﬁc, with a
positive predictive value of 81% when evaluated in the Alberta
data sets in the same time frame as this study.16,17 The ﬁrst
date a hypertension code was speciﬁed was deﬁned as the date
of diagnosis. We excluded patients with an index date between
April 1, 1994 and March 31, 1997 (3-year washout period) to
focus on patients with incident hypertension.
Figure 1. Patient ﬂowchart. HTN, hypertension.
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Hypertensive PCP UtilizationOutcomes
The primary outcome was the mean number of outpatient
PCP visits in the year after the diagnosis of hypertension.
Because the majority of patients with hypertension are
managed in the community by a PCP (Fig. 1), only outpatient
PCP services were analyzed in this study. Hypertension-
related PCP visits and the number of patients with no visits
were secondary outcomes. Hypertension-related PCP visits
were identiﬁed using ICD-9 codes 401.x, 402.x, 403.x, 404.x,
or 405.x. Patients with no PCP outpatient visits in the year
after diagnosis were considered to have not used a PCP. To
assess the association between PCP use and outcomes, we
considered death, all-cause hospitalization, cardiovascular-
speciﬁc hospitalization (ICD codes G45, G46, I60-I69,
H340, I43, I50, I099, I110, I130, I132, I255, I420, I425-
I429, P290, I21, I22, and I252 as the most responsible
diagnosis) and hypertension-speciﬁc hospitalization (ICD
codes 401.x, 402.x, 403.x, 404.x, or 405.x as the most
responsible diagnosis). All outcomes were deﬁned 1 year after
the hypertension diagnosis.
Exposure variables
Comorbidity status, deﬁned using the Charlson Comor-
bidity Index, was the exposure variable. All comorbidities were
derived from validated ICD-9/ICD-10 algorithms using both
the hospital discharge abstract data and the physician claims
database for the 3 years before the hypertension diagnosis.18,19Three categories of comorbidity were considered: (1) no co-
morbidity, (2) vascular riskerelated comorbidity (myocardial
infarction, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, diabetes with and without complica-
tions, and renal disease), and (3) unrelated comorbidity
(unrelated to vascular risk, including dementia, chronic pul-
monary obstructive disease, connective tissue disease, rheu-
matic disease, peptic ulcer disease, paraplegia/hemiplegia, liver
disease, cancer/metastatic carcinoma, and acquired immuno-
deﬁciency syndrome/human immunodeﬁciency virus infec-
tion). In the analysis considering clinical outcomes, PCP use
was the exposure variable and was categorized based on use
within other health care settings as  2 visits per year, 2-5
visits per year and  5 visits per year.20
Independent variables
Age and sex at index date of hypertension diagnosis were
deﬁned using the registry data. Age was categorized into 6
groups: < 35 years, 35-45 years, 45-55 years, 55-65 years, 65-
75 years, and > 75 years. Median income quintile was
assigned using 2001 Statistics Canada Census data and each
patient’s postal code forward sortation area.
Statistical analysis
Baseline characteristics of patients with incident hyper-
tension were analyzed descriptively. To provide a baseline
measure of use, all outcomes were calculated for both the year
Table 1. Baseline characteristics
Variable Overall
Comorbidity status
None
Vascular
related Unrelated
Total patients (n) 45,6263 28,5599 96,467 74,197
Male (%) 50.6 49.5 58.3 45.0
Age (%)
< 35 y 5.8 7.1 2.5 5.3
35-45 y 13.9 16.5 7.0 12.7
45-55 y 25.8 29.5 17.3 22.9
55-65 y 23.2 23.4 22.6 23.1
65-75 y 17.8 15.2 23.7 20.4
> 75 y 13.4 8.3 26.9 15.6
Mean age (SD) 57.6 (14.7) 54.9 (13.8) 64.6 (14.7) 59.0 (14.8)
Income quintile (%)
1 (lowest) 20.3 18.5 24.7 21.7
2 19.1 18.3 20.7 20.0
3 18.7 18.4 19.1 19.4
4 17.9 18.6 16.4 17.3
5 (highest) 17.4 19.3 13.6 15.5
Missing 6.6 7.0 5.7 6.1
Region of residence (%)
Rural 18.8 17.7 21.0 20.1
Urban 74.7 75.3 73.2 73.8
Missing 6.6 7.0 5.7 6.1
SD, standard deviation.
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Volume 30 2014preceding and the year after hypertension diagnosis. The
number of PCP visits in the year preceding and the year after
diagnosis was estimated using zero-inﬂation Poisson regression
to account for the overdispersion resulting from excessive zero
counts. If the Poisson assumption that variance is equal to the
mean was not met, negative binominal regression was used. If
hypertension was deﬁned using physician claims, the 2 visits
required to meet the deﬁnition of hypertension were not
included in estimates of the mean number of visits. Both
crude and adjusted means are reported. The adjusted model
included age group, sex, income quintile, rural/urban resi-
dence, and year of diagnosis. To assess if use patterns changed
over time, the mean number of PCP visits was calculated by
year of diagnosis. A c2 test for trend was completed for each
comorbidity group over time. A proportional hazard Cox
model was completed to assess the association between PCP
use and clinical outcomes, including death and all-cause,
cardiovascular, and hypertension-speciﬁc hospitalization.
Because of the time-dependent nature of PCP exposure, only
adjusted analyses were considered. A time-dependent variable
was included to account for the relationship between PCP use
and exposure time. All analyses were adjusted for age, sex,
income quintile, rural/urban dwelling, and year of diagnosis.
The statistical analyses were conducted using Statistical
Analysis software (SAS), version 9.3 (SAS Institute, Cary,
NC). Ethics approval was obtained from the Conjoint Health
Research Ethics Board at the University of Calgary.Results
In total, 456,263 patients (mean age, 57.6 years; 50.6%
men) with newly diagnosed hypertension were identiﬁed in
ﬁscal years 1998-2008, the majority of whom (62.5%) had no
comorbidities at the time of the hypertension diagnosis
(Table 1). Patients with newly diagnosed hypertension and no
comorbidities were more likely to be younger, have a higher
income, and be urban dwellers (Table 1). The vast majority of
our cohort was diagnosed with hypertension on the basis of 2
outpatient clinic visits (90.1%).
In the year preceding the diagnosis of hypertension,
7,386,681 physician claims were submitted within our cohort
(Fig. 1). Of those, 4,933,038 were excluded because they were
for diagnostic and therapeutic services, in-patient services, day
surgical procedures, or emergency department visits. An
additional 220,346 claims (3.0% of the total number of
claims) were excluded because the service provider specialty
was an internal medicine specialist in an outpatient clinic
rather than a PCP (eg, it was a visit with general internal
medicine, cardiology, or nephrology physicians). The
remaining 2,233,297 outpatient PCP claims were included in
the analysis in the year preceding hypertension diagnosis.
Similarly, in the year after the hypertension diagnosis,
8,888,886 physician claims were submitted. Of those,
5,499,698 were excluded because they were for diagnostic and
therapeutic services, in-patient services, day surgical pro-
cedures, or emergency department visits, and 271,710 were
excluded (3.1% of the total number of claims) because they
were internal medicine specialist outpatient visits. The
remaining 3,389,188 outpatient PCP claims in the year after
diagnosis were included. Of note, only 4228 of our incident
hypertension cohort (0.93%) were seen solely by an internalmedicine specialist as an outpatient in the year after diagnosis
and had no PCP visits.
More than 88% of all patients had seen a PCP at least once
in the year before the diagnosis of hypertension (Supplemental
Table S1), and the frequency of PCP visits for any indication
increased after the diagnosis of hypertension in all 4
comorbidity-deﬁned subgroups. As expected, the mean
number of visits among patients with comorbidities was
higher than those with no comorbidities both before and after
the diagnosis of hypertension. Generally, the mean number of
visits was higher among women than men and among older
age groups than younger age groups, but use patterns did not
vary substantially across rural vs urban regions or by socio-
economic status. The majority of the increase in PCP visits
observed from the year preceding diagnosis to the year after
diagnosis was accounted for by hypertension-related visits
(Supplemental Table S1). The absolute (and relative) increase
was greater in those with no comorbidities compared with
those with at least 1 comorbidity. Individuals younger than 35
years of age, men, and those from lower income quintiles had
higher percentages of patients with no PCP visits
(Supplemental Table S2). However, it should be noted that
even in these “underserved” subgroups, more than 90% of
patients had at least 1 PCP visit in the year after the diagnosis
of hypertension.
The mean number of PCP visits before the hypertension
diagnosis remained stable from 1998-2008 across all co-
morbidity subgroups (Fig. 2) (no comorbidity, P ¼ 0.47;
vascular risk related, P ¼ 0.93; unrelated, P ¼ 0.41). The
adjusted model included age, sex, urban/rural dwelling, and
income quintile. However, the adjusted mean number of
visits after diagnosis appeared to decline over time (Fig. 3),
with a statistically signiﬁcant decline among those with no
comorbidities (P ¼ 0.01), vascular riskerelated comorbid-
ities (P < 0.001), and unrelated comorbidities (P ¼ 0.002).
Figure 2. Adjusted mean number of primary care physician (PCP) visits in the year preceding hypertension diagnosis stratiﬁed by comorbidity
subgroups, 1998-2008. Results are adjusted for sex, age, urban/rural dwelling, and income quintile.
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Hypertensive PCP UtilizationThere were large variations in the risk of death across the
comorbidity subgroups (Table 2). Compared with patients
with  2 PCP visits, those with  5 visits had a signiﬁcantly
lower risk of death (ranging from a hazard ratio of 0.07; 95%
conﬁdence interval [CI], 0.06-0.07 for those with vascular-
related comorbidities to a hazard ratio of 0.16; 95% CI,
0.15-0.18 for those with none). As consistently found in other
clinical groups, those with higher PCP use have higher rates of
hospitalization; high users of PCPs are high users of the health
care system more generally.20-23Discussion
Among this population-based cohort of patients with
incident hypertension, we found that > 88% of patients
visited a PCP at least once in the year before diagnosis, and >
94% saw a PCP in the year after the hypertension diagnosis.
The mean number of visits after diagnosis increased by
approximately 2 (in patients without comorbidities) and
approximately 1.5 (in patients with at least 1 comorbidity)
compared with the preceding year, over and above the 2 visits
required for meeting the hypertension case deﬁnition. The
majority of the increase was accounted for by visits coded by
the attending physician as being hypertension related. Patterns
of prediagnosis PCP visits did not change appreciably over the
10-year study period; however, there was a small but real
decline in the mean number of PCP visits in the year after
diagnosis. Finally, increased PCP use was associated with a
lower risk of death but increased risk of hospitalization.
There are several possible explanations for the decrease in
visits over time. First, patients may be more likely to be seen
by specialists in more recent years. However, in an exploratoryanalysis, the crude mean number of visits to non-PCPs
(including surgeons, internists, cardiologists, nephrologist,
and so on) had decreased from 0.52 (0.50-0.53) in 1998 to
0.38 (0.37-0.39) in 2008 among those with no comorbidities
and from 1.57 (1.49-1.65) in 1998 to 1.13 (1.08-1.20) in
2008 among those with any comorbidity. Thus, the decrease
in PCP visits was mirrored by a decrease in specialist visits,
arguing against a shift from PCP follow-up to specialist
follow-up.
Second, patients may be achieving better control of their
blood pressure and thus require fewer visits. Although this
study is unable to provide evidence to support or refute this
claim, because we do not have patient-level blood pressure
measurements, other studies have found no relationship be-
tween blood pressure control and the intensity of PCP use.24
Thus, the decline in the mean number of visits over time is
unlikely to be attributable to better blood pressure control.
Third, the decline over time may be related to changes in
mortality over time, combined with a younger age of onset for
the diagnosis of hypertension. If the 1-year death risk has
signiﬁcantly increased among patients with newly diagnosed
hypertension, the mean PCP use may appear to decrease over
time simply because of at-risk time. However, national Ca-
nadian data demonstrate that the risk of death has decreased
over time,25 and with improvements in identiﬁcation, treat-
ment, and education programs available, patients are diag-
nosed and treated at a younger age.26
Finally, changes in models of care may have impacted the
PCP use rates. However, primary care networks (models of
care that provide comprehensive disease management pro-
grams that may result in patients being seen by a nurse as
opposed to a PCP) were introduced in Alberta in 2002. Our
Figure 3. Adjusted mean number of primary care physician (PCP) visits in the year after hypertension diagnosis stratiﬁed by comorbidity subgroups,
1998-2008. Results are adjusted for sex, age, urban/rural dwelling, and income quintile.
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Volume 30 2014study documents a constant decrease in PCP visits from 1998
onward in both complicated and uncomplicated patients with
hypertension arguing that changes in care models cannot ac-
count for all the observed decrease and that the impact would
have affected all groups equally.
Our study suggests that PCP access at the population level
is being achieved; the vast majority of patients had PCP visits
before and after diagnosis, and use patterns did not vary
substantially by rural/urban regions or by income quintile.
This ﬁnding disproves 1 hypothesis for why an earlier Alberta-
based study found markedly higher rates of ambulatory
careesensitive hospitalizations among uncomplicated hyper-
tensive patients from rural areas or those with lower household
income levels.27
Given the emphasis in current hypertension guidelines on
absolute cardiovascular risk and the need to address all car-
diovascular risk factors, we had anticipated that patients with
multiple cardiovascular risk factors would have exhibited a
greater increase in PCP visit frequency after the diagnosis of
hypertension than those without any other cardiovascular risk
factors. Indeed, our ﬁnding that this was not true perhaps
helps explain recent reports that other cardiovascular risk
factors are not any better controlled in patients with hyper-
tension than in those without hypertension.28-31 Alternatively,
perhaps these patients had few reasons to see a PCP previ-
ously; however, with the diagnosis of hypertension, they are
required to visit more frequently for the evaluation of possible
underlying causes and risk factors (eg, hyperlipidemia, dia-
betes, or renal function impairment).
Our ﬁnding that increased PCP use was associated with a
decrease in the risk of death but an increase in the risk ofhospitalization is similar to ﬁndings from other groups.20-22
There are several possible explanations for this ﬁnding. First,
the result may be caused by the time-dependent nature of the
PCP user deﬁnition. To be classiﬁed as a high user, a patient
must survive long enough to complete 5 or more PCP visits.
Second, there may be clinical and demographic differences
between the different PCP use cohorts; patients who see their
PCP more often may have different underlying health issues
than those who do not. Indeed, it is likely that high PCP users
are more likely to have multiple comorbidities and require
more frequent health care visits to manage their diseases.
However, the optimal PCP use to achieve maximum clinical
beneﬁt without incurring additional, perhaps unrequired,
physician visit costs remains unknown. Future work should
focus on assessing the appropriate number of PCP visits
required to maximize health beneﬁt.
Our study has limitations. First, only visits with a PCP in
an outpatient ofﬁce are included. This deﬁnition excludes any
visits to PCP clinics within a hospital. However, given that the
majority (90%) of primary care physicians in Alberta work in
outpatient clinics,32 this is unlikely to introduce substantial
bias. In addition, any outpatient visits to a specialistdsuch as
an internist, nephrologist, or cardiologistdwere not consid-
ered in our main analysis; however, this bias will be small
because those visits accounted for only 3% of the physician
claims in both the prediagnosis and postdiagnosis intervals. To
be included in our cohort, patients had to meet the deﬁnition
of hypertension using administrative data (either 2 physician
claims or 1 hospitalization). The visits required to meet the
deﬁnition of hypertension are excluded from the number of
visits in all our analyses. Thus, the data we report is for the
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Clement et al. 659
Hypertensive PCP Utilizationnumber of PCP visits over and above the 2 needed for
meeting the case deﬁnition. Our analysis does not take into
account physician visits for hospitalized patients, but only
1.6% of this cohort was hospitalized in the year after the
initial diagnosis of hypertension. In addition, patients who
died in the ﬁrst year after diagnosis of hypertension contrib-
uted follow-up intervals that were shorter than 1 year. Because
the death risk varied across comorbidity subgroups, we
completed a sensitivity analysis calculating the mean PCP use
in the year after diagnosis in the cohort of patients that sur-
vived the entire year of follow-up to ensure that death was not
a source of differential bias across comorbidity subgroups. Our
results were remarkably similar, demonstrating that death was
not a source of signiﬁcant bias in our analysis. Finally, we
analyzed Alberta data, and the resource use patterns we
observed may differ in other Canadian provinces. This study
should be replicated in other jurisdictions.
In conclusion, we found that the frequency of PCP visits
for patients with a new diagnosis of hypertension was very
high, with > 88% of patients visiting a PCP at least once
before diagnosis, and > 94% of patients seeing a PCP at least
once in the year after diagnosis, even after excluding diagnosis-
related visits. We found a small but statistically signiﬁcant
decline over time in the frequency of PCP visits after the
diagnosis of hypertension. Future studies should examine the
optimal patterns of outpatient visits for patients with hyper-
tension to achieve the most cost-effective use of scarce PCP
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